Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Shed-MEDS: pilot of a patient-centered deprescribing framework reduces medications in hospitalized older adults being transferred to inpatient postacute care.

Petersen AW, Shah AS, Simmons SF, Shotwell MS, Jacobsen JML, Myers AP, Mixon AS, Bell SP, Kripalani S, Schnelle JF, Vasilevskis EE.

Ther Adv Drug Saf. 2018 Jun 15;9(9):523-533. doi: 10.1177/2042098618781524. eCollection 2018 Sep.

2.

Towards mapping electrostatic interactions between Kdo2-lipid A and cationic antimicrobial peptides via ultraviolet photodissociation mass spectrometry.

Crittenden CM, Morrison LJ, Fitzpatrick MD, Myers AP, Novelli ET, Rosenberg J, Akin LD, Srinivasa V, Shear JB, Brodbelt JS.

Analyst. 2018 Jul 23;143(15):3607-3618. doi: 10.1039/c8an00652k.

PMID:
29968868
3.

Medications associated with geriatric syndromes and their prevalence in older hospitalized adults discharged to skilled nursing facilities.

Saraf AA, Petersen AW, Simmons SF, Schnelle JF, Bell SP, Kripalani S, Myers AP, Mixon AS, Long EA, Jacobsen JM, Vasilevskis EE.

J Hosp Med. 2016 Oct;11(10):694-700. doi: 10.1002/jhm.2614. Epub 2016 Jun 3.

4.

Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.

Myers AP, Filiaci VL, Zhang Y, Pearl M, Behbakht K, Makker V, Hanjani P, Zweizig S, Burke JJ 2nd, Downey G, Leslie KK, Van Hummelen P, Birrer MJ, Fleming GF.

Gynecol Oncol. 2016 Apr;141(1):43-8. doi: 10.1016/j.ygyno.2016.02.025.

5.

PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients.

Westin SN, Ju Z, Broaddus RR, Krakstad C, Li J, Pal N, Lu KH, Coleman RL, Hennessy BT, Klempner SJ, Werner HM, Salvesen HB, Cantley LC, Mills GB, Myers AP.

Mol Oncol. 2015 Oct;9(8):1694-703. doi: 10.1016/j.molonc.2015.04.014. Epub 2015 May 16.

6.

Loss of native rocky reef biodiversity in Australian metropolitan embayments.

Stuart-Smith RD, Edgar GJ, Stuart-Smith JF, Barrett NS, Fowles AE, Hill NA, Cooper AT, Myers AP, Oh ES, Pocklington JB, Thomson RJ.

Mar Pollut Bull. 2015 Jun 15;95(1):324-32. doi: 10.1016/j.marpolbul.2015.03.023. Epub 2015 Apr 14.

PMID:
25882229
7.

Drug reaction with eosinophilia and systemic symptoms syndrome probably induced by a lamotrigine-ginseng drug interaction.

Myers AP, Watson TA, Strock SB.

Pharmacotherapy. 2015 Mar;35(3):e9-e12. doi: 10.1002/phar.1550. Epub 2015 Mar 10.

PMID:
25756365
8.

Characteristics associated with postdischarge medication errors.

Mixon AS, Myers AP, Leak CL, Lou Jacobsen JM, Cawthon C, Goggins KM, Nwosu S, Schildcrout JS, Schnelle JF, Speroff T, Kripalani S.

Mayo Clin Proc. 2014 Aug;89(8):1042-51. doi: 10.1016/j.mayocp.2014.04.023. Epub 2014 Jul 3.

9.

A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition.

Cheng H, Liu P, Zhang F, Xu E, Symonds L, Ohlson CE, Bronson RT, Maira SM, Di Tomaso E, Li J, Myers AP, Cantley LC, Mills GB, Zhao JJ.

Cancer Res. 2014 Jan 1;74(1):15-23. doi: 10.1158/0008-5472.CAN-13-0544. Epub 2013 Dec 9.

10.

What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway.

Klempner SJ, Myers AP, Cantley LC.

Cancer Discov. 2013 Dec;3(12):1345-54. doi: 10.1158/2159-8290.CD-13-0063. Epub 2013 Nov 21. Review.

11.

New strategies in endometrial cancer: targeting the PI3K/mTOR pathway--the devil is in the details.

Myers AP.

Clin Cancer Res. 2013 Oct 1;19(19):5264-74. doi: 10.1158/1078-0432.CCR-13-0615. Review.

12.

Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix.

Wright AA, Howitt BE, Myers AP, Dahlberg SE, Palescandolo E, Van Hummelen P, MacConaill LE, Shoni M, Wagle N, Jones RT, Quick CM, Laury A, Katz IT, Hahn WC, Matulonis UA, Hirsch MS.

Cancer. 2013 Nov 1;119(21):3776-83. doi: 10.1002/cncr.28288. Epub 2013 Aug 23.

13.

Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.

Klempner SJ, Myers AP, Mills GB, Westin SN.

Expert Opin Pharmacother. 2013 Nov;14(16):2171-82. doi: 10.1517/14656566.2013.826650. Epub 2013 Aug 12. Review.

14.

Repurposing the Pap smear: one step closer to gynecologic cancer screening.

Westin SN, Mills GB, Myers AP.

Sci Transl Med. 2013 Jan 9;5(167):167ps1. doi: 10.1126/scitranslmed.3005411.

15.

Sugar free, cancer free?

Myers AP, Cantley LC.

Nutrition. 2012 Oct;28(10):1036. doi: 10.1016/j.nut.2012.07.004. No abstract available.

16.

High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.

Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB.

Cancer Discov. 2011 Jul;1(2):170-85. doi: 10.1158/2159-8290.CD-11-0039. Epub 2011 Jun 7. Erratum in: Cancer Discov. 2012 Aug;2(8):750-1.

17.

Targeting a common collaborator in cancer development.

Myers AP, Cantley LC.

Sci Transl Med. 2010 Sep 8;2(48):48ps45. doi: 10.1126/scitranslmed.3001251.

18.

Getting knit-PI3Ky: PIK3CA mutation status to direct multimodality therapy?

Myers AP, Meyerhardt JA, Cantley LC.

Clin Cancer Res. 2009 Nov 15;15(22):6748-50. doi: 10.1158/1078-0432.CCR-09-2305. Epub 2009 Nov 10.

19.

Micro-geographic risk factors for malarial infection.

Myers WP, Myers AP, Cox-Singh J, Lau HC, Mokuai B, Malley R.

Malar J. 2009 Feb 13;8:27. doi: 10.1186/1475-2875-8-27.

20.

Essential and opposing roles of zebrafish beta-catenins in the formation of dorsal axial structures and neurectoderm.

Bellipanni G, Varga M, Maegawa S, Imai Y, Kelly C, Myers AP, Chu F, Talbot WS, Weinberg ES.

Development. 2006 Apr;133(7):1299-309. Epub 2006 Mar 1.

21.

Supplemental Content

Loading ...
Support Center